ATOS
Income statement / Annual
Last year (2024), Atossa Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Atossa Therapeutics, Inc.'s net income was -$25.50 M.
See Atossa Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1,758.00 |
| Cost of Revenue |
$17,000.00
|
$23,000.00
|
$8,000.00
|
$23,000.00
|
$46,600.00
|
$52,789.00
|
$44,197.00
|
$128,994.00
|
$303,482.00
|
$132,411.00
|
| Gross Profit |
-$17,000.00
|
-$23,000.00
|
-$8,000.00
|
-$23,000.00
|
-$46,600.00
|
-$52,789.00
|
-$44,197.00
|
-$128,994.00
|
-$303,482.00
|
-$130,653.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-74.32
|
| Research and Development Expenses |
$14.12 M
|
$17.33 M
|
$15.08 M
|
$9.21 M
|
$6.61 M
|
$6.65 M
|
$4.21 M
|
$2.33 M
|
$770,427.00
|
$2.36 M
|
| General & Administrative Expenses |
$0.00
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
$8.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.42 M
|
| Selling, General & Administrative Expenses |
$13.49 M
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
$10.27 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$146,000.00
|
-$85,000.00
|
$50,801.00
|
$25,648.00
|
$29,299.00
|
$154.00
|
$718,970.00
|
$0.00
|
| Operating Expenses |
$27.60 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.19 M
|
$7.25 M
|
$12.63 M
|
| Cost And Expenses |
-$27.62 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.19 M
|
$7.25 M
|
$12.76 M
|
| Interest Income |
$4.05 M
|
$4.34 M
|
$877,000.00
|
$6,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$192,817.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$17,000.00
|
$23,000.00
|
$8,000.00
|
$23,000.00
|
$46,600.00
|
$52,789.00
|
$44,197.00
|
$128,994.00
|
$303,482.00
|
$272,627.00
|
| EBITDA |
-$25.49 M |
-$31.35 M |
-$27.68 M |
-$20.50 M |
-$14.56 M |
-$17.21 M |
-$11.39 M |
-$7.80 M |
-$6.37 M |
-$12.49 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7102.38
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7257.46
|
| Total Other Income/Expenses Net |
$2.12 M
|
$1.28 M
|
$731,000.00
|
-$85,000.00
|
-$3.22 M
|
$25,648.00
|
$29,299.00
|
-$473,410.00
|
$0.00
|
$431.00
|
| Income Before Tax |
-$25.50 M
|
-$30.09 M
|
-$26.96 M
|
-$20.61 M
|
-$17.83 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
-$12.76 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7257.22
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$731,000.00
|
-$213,558.00
|
$3.27 M
|
-$119,071.00
|
-$29,299.00
|
$742,462.00
|
-$1.76 M
|
$3.00 M
|
| Net Income |
-$25.50 M
|
-$30.09 M
|
-$26.23 M
|
-$20.61 M
|
-$21.10 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
-$15.76 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-8964.92
|
| EPS |
-0.2 |
-0.24 |
-0.21 |
-0.18 |
-1.87 |
-2.03 |
-2.74 |
-8.33 |
-25.93 |
-99.79 |
| EPS Diluted |
-0.2 |
-0.24 |
-0.21 |
-0.18 |
-1.87 |
-2.03 |
-2.74 |
-8.33 |
-25.93 |
-99.79 |
| Weighted Average Shares Out |
$125.86 M
|
$126.08 M
|
$126.62 M
|
$116.95 M
|
$11.31 M
|
$8.50 M
|
$4.16 M
|
$974,768.00
|
$245,605.00
|
$157,930.00
|
| Weighted Average Shares Out Diluted |
$125.86 M
|
$126.08 M
|
$126.62 M
|
$116.95 M
|
$11.31 M
|
$8.50 M
|
$4.16 M
|
$974,768.00
|
$245,605.00
|
$157,930.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
